Aligos Therapeutics, Inc. (ALGS)
NASDAQ: ALGS · IEX Real-Time Price · USD
0.782
-0.036 (-4.40%)
At close: Apr 26, 2024, 4:00 PM
0.786
+0.004 (0.50%)
After-hours: Apr 26, 2024, 7:22 PM EDT
Aligos Therapeutics Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Aligos Therapeutics.
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for ALGS.
Recommendation Trends
| Rating | Aug '22 | Sep '22 | Oct '22 | Nov '22 | Dec '22 | Jan '23 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 3 | 3 | 3 | 3 | 3 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 0 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $3 → $7 | Buy | Maintains | $3 → $7 | +795.14% | Jan 17, 2023 |
| Piper Sandler | Piper Sandler | Hold → Buy Upgrades $2 → $3 | Hold → Buy | Upgrades | $2 → $3 | +283.63% | Jan 6, 2023 |
| Jefferies | Jefferies | Hold → Strong Buy Upgrades $2.5 → $3 | Hold → Strong Buy | Upgrades | $2.5 → $3 | +283.63% | Jan 6, 2023 |
| SVB Leerink | SVB Leerink | Hold Maintains $3 → $2 | Hold | Maintains | $3 → $2 | +155.75% | Nov 3, 2022 |
| SVB Leerink | SVB Leerink | Buy → Hold Downgrades $7 → $3 | Buy → Hold | Downgrades | $7 → $3 | +283.63% | May 5, 2022 |
Financial Forecast
Revenue This Year
n/a
from 15.53M
Revenue Next Year
n/a
EPS This Year
-0.85
from -1.36
EPS Next Year
-0.84
from -0.85
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | 128.1M | 425.4M |
| Avg | n/a | n/a | n/a | 62.2M | 328.5M |
| Low | n/a | n/a | n/a | n/a | 234.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 583.6% |
| Avg | - | - | - | - | 427.9% |
| Low | - | - | - | - | 276.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.87 | -0.68 | -0.74 | -2.57 | 1.68 |
| Avg | -0.85 | -0.84 | -0.97 | -2.50 | 1.63 |
| Low | -0.82 | -0.97 | -1.18 | -2.40 | 1.57 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.